<DOC>
	<DOCNO>NCT02133846</DOCNO>
	<brief_summary>The purpose study determine safety tolerability [ maximum tolerate dose ( MTD ) within plan dose range ] intravenous ( IV ) infusion TPI 287 administer every 3 week 9 week ( total 4 infusion ) patient primary four repeat tauopathies ( 4RT ) , corticobasal syndrome ( CBS ; also call corticobasal degeneration , CBD ) progressive supranuclear palsy ( PSP ) .</brief_summary>
	<brief_title>Safety Study TPI-287 Treat CBS PSP</brief_title>
	<detailed_description>The maximum tolerated dose TPI-287 determine plan dose escalation 3 sequential cohort , comprise 11 participant randomize either TPI-287 placebo . TPI-287 placebo administer intravenous infusion every 3 week 9 week , total 4 infusion . Participants successfully complete phase option enter open label extension phase TPI-287 administer every 3 week additional 6 week , total 3 extra infusion . The dose TPI 287 escalate sequential cohort . In low dose cohort 11 subject diagnosis ( i.e. , separate dose escalation perform CBS PSP ) enrol . The medium high dose cohort comprise 11 subject ; combine CBS PSPdiagnoses . Subjects assign cohort order study entry . Pre-medications diphenhyramine 25 mg ( Benadryl ) , dexamethasone 10 mg , famotidine 20 mg ( H2 blocker ranitidine 50 mg ) give IV within 60 minute prior study infusion . Safety tolerability assess report adverse event , physical neurological testing , ECGs , well blood urine analysis . Baseline end-point measure cognition function , MRI brain scan , cerebrospinal fluid ( CSF ) biomarker analysis use determine preliminary efficacy TPI-287 mild-moderate AD . Pharmacokinetic pharmacodynamic property TPI-287 calculate blood plasma collect first infusion , CSF collect last visit placebo-controlled phase .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Supranuclear Palsy , Progressive</mesh_term>
	<mesh_term>Tauopathies</mesh_term>
	<criteria>1 . Between 50 85 year age ( inclusive ) ; 2 . Able walk 5 step minimal assistance ( stabilization one arm use cane/walker ) ; 3 . MRI Screening consistent CBS PSP ( â‰¤ 4 microhemorrhages , large stroke severe white matter disease ) ; 4 . MMSE Screening 14 30 ( inclusive ) ; 5 . FDAapproved AD medication sometimes prescribe CBS PSP subject , allow long dose stable 2 month prior Screening . Other medication ( except list exclusion criterion ) allow long dose stable 30 day prior Screening ; 6 . FDAapproved Parkinson 's medication allow long dose stable 2 month prior Screening ; 7 . Has reliable study partner agree accompany subject visit , spend least 5 hour per week subject ; 8 . Agrees 2 lumbar puncture ; 9 . Signed date write informed consent obtain subject subject 's caregiver accordance local IRB regulation ; 10 . Males WCBP agree abstain sex use adequate method contraception duration study 30 day last dose study drug . Adequate contraceptive method include low failure rate , i.e. , less 1 % per year , use consistently correctly , complete abstinence sexual intercourse potentially fertile partner , double barrier method ( condom spermicide ) conjunction use partner intrauterine device ( IUD ) , diaphragm spermicide , oral contraceptive , birth control patch vaginal ring , oral , injectable implanted contraceptive . For study , woman surgically sterilize state amenorrhea two year deem childbearing potential ; For PSP Only 11 . Meets National Institute Neurological Disorders Stroke Society Progressive Supranuclear Palsy ( NINDSSPSP ) probable possible PSP criterion ( Litvan et al . 1996a ) , modify Neuroprotection Natural History Parkinson Plus Syndromes ( NNIPPS ) clinical trial ( Bensimon et al . 2009 ) . For CBS Only 11 . Meets 2013 consensus criterion possible probable corticobasal degeneration , CBS subtype ( Armstrong et al . 2013 ) . 1 . Meets National Institute AgingAlzheimer 's Association Workgroups criterion probable AD ( McKhann et al . 2011 ) ; 2 . Any medical condition CBS PSP could account cognitive deficit ( e.g. , active seizure disorder , stroke , vascular dementia ) ; 3 . A prominent sustain response levodopa therapy ; 4 . History significant cardiovascular , hematologic , renal , hepatic disease ( laboratory evidence thereof ) ; 5 . History significant peripheral neuropathy ; 6 . History major psychiatric illness untreated depression ; 7 . Neutrophil count &lt; 1,500/mm3 , platelet &lt; 100,000/mm3 , serum creatinine &gt; 1.5 x upper limit normal ( ULN ) , total bilirubin &gt; 1.5 x ULN , alanine aminotransferase ( ALT ) &gt; 3 x ULN , aspartate aminotransferase ( AST ) &gt; 3 x ULN , INR &gt; 1.2 Screening evaluation ; 8 . Evidence clinically significant finding Screening baseline evaluation , opinion Investigator would pose safety risk interfere appropriate interpretation study data ; 9 . Current recent history ( within four week prior Screening ) clinically significant bacterial , fungal , mycobacterial infection ; 10 . Current clinically significant viral infection ; 11 . Major surgery within four week prior Screening ; 12 . Unable tolerate MRI scan Screening ; 13 . Any contraindication unable tolerate lumbar puncture Screening , include use anticoagulant medication warfarin . Daily administration 81 mg aspirin allow long dose stable 30 day prior Screening ; 14 . Subjects , opinion Investigator , unable unlikely comply dose schedule study evaluation ; 15 . Previous exposure microtubule inhibitor ( include TPI 287 ) within 5 year Screening . Treatment microtubule inhibitor TPI 287 study allow ; 16 . Participation another interventional clinical trial within 3 month Screening ; 17 . Treatment another investigational drug within 30 day Screening . Treatment investigational drug TPI 287 study allow ; 18 . Known hypersensitivity inactive ingredient study drug ; 19 . Pregnant lactating ; 20 . Positive pregnancy test Screening Baseline ( Day 1 ) ; 21 . Cancer within 5 year Screening , except nonmetastatic skin cancer nonmetastatic prostate cancer expect cause significant morbidity mortality within one year baseline . For CBS Only : 22 . History evidence Screening cortical amyloid level 18F florbetapir PET scan consistent underlie AD ; 23 . History serum plasma progranulin level le one standard deviation normal subject mean laboratory perform assay ; 24 . History evidence Screening know diseaseassociated mutation GRN C9ORF72 gene rule CBS due TDP43 pathology ; 25 . History know diseaseassociated mutation ribosomal protein L3 [ TDP 43 gene ( TARBP ) ] , chromatin modify protein 2B ( CHMPB2 ) valosin contain protein ( VCP ) gene frontotemporal lobar degeneration ( FTLD ) causative gene discover course trial associate underlying tau pathology .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>4RT , CBS , PSP , CBD , TPI-287</keyword>
</DOC>